This course introduces key contemporary and emerging issues in the US healthcare and pharmaceutical industry. Part I provides (a) a grounding in the industry’s institutional features, in particular the role played by the Food and Drug Administration (FDA) in regulating the sector, (b) an overview of key stakeholders involved in drug launch and commercialization, and (c) each stakeholders economic incentives in this competitive market. Once students understand the landscape, stakeholders, and incentives, Part II will turn to (a) the interplay between the stakeholders, (b) the current and anticipated changes to this highly dynamic industry, and (c) focus on recent Policy updates, emerging product categories, and a critical consideration of the future of healthcare delivery and payment in the US.
